Inluriyo
- Product NDC
- 0002-1717
- 11-digit product format
- 000021717
- Labeler code
- 0002
- Product ID
- 0002-1717_1ece6e73-2242-434e-b297-7ccf07a54c1e
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- imlunestrant
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Eli Lilly and Company
- Application
- NDA218881
- Marketing category
- NDA
- Marketing start
- 2025-09-25
- Substance
- IMLUNESTRANT
- Active strength
- 200 mg/1
- Pharmacologic classes
- Breast Cancer Resistance Protein Inhibitors [MoA], Estrogen Receptor Antagonist [EPC], Estrogen Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Inluriyo
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| IMLUNESTRANT | 200 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 9CXQ3PF69U |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 0002-1717-28 | Inluriyo | 28 in 1 BOTTLE | TABLET, FILM COATED | 28 | | 6 |
| 0002-1717-56 | Inluriyo | 56 in 1 BOTTLE | TABLET, FILM COATED | 56 | | 6 |
| 0002-1717-61 | Inluriyo | 56 in 1 BOTTLE | TABLET, FILM COATED | 56 | | 6 |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 0002-1717-28 | 00002171728 | 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) | 2025-10-16 | No | No | Current |
| 0002-1717-56 | 00002171756 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) | 2025-10-15 | No | No | Current |
| 0002-1717-61 | 00002171761 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61) | 2025-11-13 | Yes | No | Current |